QURE uniQure N.V.

Nasdaq uniqure.com


$ 31.23 $ 0.00 (0 %)    

Tuesday, 04-Nov-2025 08:01:09 EST
QQQ $ 623.45 $ 0.00 (0 %)
DIA $ 470.57 $ 0.00 (0 %)
SPY $ 676.45 $ 0.00 (0 %)
TLT $ 89.78 $ 0.00 (0 %)
GLD $ 366.50 $ 0.00 (0 %)
$ 34.29
$ 23.20
$ 31.20 x 51
$ 31.40 x 2
-- - --
$ 5.35 - $ 71.50
30,500,286
na
1.88B
$ 1.28
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 11-05-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-01-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-02-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 10-25-2021 09-30-2021 10-Q
17 07-26-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 10-27-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-29-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 10-28-2019 09-30-2019 10-Q
25 07-29-2019 06-30-2019 10-Q
26 04-29-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 04-30-2018 03-31-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-01-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 william-blair-downgrades-uniqure-to-market-perform

William Blair analyst Sami Corwin downgrades uniQure (NASDAQ:QURE) from Outperform to Market Perform.

 hc-wainwright--co-maintains-buy-on-uniqure-lowers-price-target-to-70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target f...

 chardan-capital-maintains-buy-on-uniqure-lowers-price-target-to-53

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $76 to $53.

 uniqure-shares-drop-after-fda-shifts-stance-on-huntingtons-gene-therapy-data

UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's dise...

 uniqure-receives-feedback-from-fda-during-pre-bla-meeting-regarding-amt-130-investigational-gene-therapy-for-hd

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical ...

 why-is-protalix-biotherapeutics-stock-falling-on-friday

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data ...

 cramer-warns-on-one-chip-stock-says-broadcom-is-the-better-bet

Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises se...

 hc-wainwright--co-maintains-buy-on-uniqure-raises-price-target-to-110

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy and raises the price target f...

 wells-fargo-maintains-overweight-on-uniqure-raises-price-target-to-80

Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the price target from $65 to $80.

 benzinga-bulls-and-bears-oracle-costco-nio--and-wall-street-snaps-its-slide

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...

 goldman-sachs-maintains-neutral-on-uniqure-raises-price-target-to-56

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ: QURE) with a Neutral and raises the price target from $13 t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION